# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 27, 2023

#### **BONE BIOLOGICS CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction of incorporation)

**001-40899** (Commission File Number)

42-1743430 (IRS Employer Identification No.)

2 Burlington Woods Drive, Ste. 100
Burlington, MA
(Address of principal executive offices)

**01803** (Zip Code)

Registrant's telephone number, including area code: (781) 552-4452

Securities registered pursuant to section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.001 par value per share	BBLG	The Nasdaq Stock Market LLC
Warrants to Purchase Common stock, \$0.001 par value per share	BBLGW	The Nasdaq Stock Market LLC
Check the appropriate box below if the Form 8-K filin any of the following provisions (see General Instruction		sly satisfy the filing obligation of the registrant under
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
Indicate by check mark whether the registrant is an e (§230.405 of this chapter) or Rule 12b-2 of the Securit		
Emerging growth company $\square$		
If an emerging growth company, indicate by check complying with any new or revised financial accounting	_	

## Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 27, 2023 Erick Lucera resigned as a director of the Company, effective upon the appointment of a new director. The resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. The Company is appreciative of Mr. Lucera's years of service to the Company as a director.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 02, 2024 BONE BIOLOGICS CORPORATION

By: /s/JEFFREY FRELICK

Name: Jeffrey Frelick

Title: Chief Executive Officer